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Abstract
Background and Aim: The human asialoglycoprotein receptor is a membrane heterooligomer expressed exclusively in
hepatocytes. A soluble secreted form, sH2a, arises, not by shedding at the cell surface, but by intracellular cleavage of its
membrane-bound precursor, which is encoded by an alternatively spliced form of the receptor H2 subunit. Here we
determined and report that sH2a, present at constant levels in serum from healthy individuals is altered upon liver fibrosis,
reflecting the status of hepatocyte function.
Methods: We measured sH2a levels in serum using a monoclonal antibody and an ELISA assay that we developed,
comparing with routine liver function markers. We compared blindly pretreatment serum samples from a cohort of 44
hepatitis C patients, which had METAVIR-scored biopsies, with 28 healthy individuals.
Results: sH2a levels varied minimally for the healthy individuals (150621 ng/ml), whereas the levels deviated from this
normal range increasingly in correlation with fibrosis stage. A simple algorithm combining sH2a levels with those of alanine
aminotransferase allowed prediction of fibrosis stage, with a very high area under the ROC curve of 0.86.
Conclusions: sH2a has the potential to be a uniquely sensitive and specific novel marker for liver fibrosis and function.
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Introduction
A soluble secreted form of the human asialoglycoprotein receptor
(ASGPR), termed sH2a, is formed by cleavage in the endoplasmic
reticulum of hepatocytes of its precursor [1], encoded by an
alternatively spliced variant of the ASGPR H2 subunit mRNA [2].
We recently reported that sH2a is present at constant levels in the
serum of healthy individuals [3]. The ASGPR is expressed to a
significant degreeonlyinhepatocytes[4]and serves inthe clearance
of asialoglycoproteins from the plasma [5]. Several conditions
correlate with a significant reduction in the levels of the ASGPR,
among them hepatocyte dedifferentiation [6,7], chronic alcohol
consumption [8] and liver fibrosis and cirrhosis [9,10]. We found
that the levels of sH2a are also significantly reduced in a pilot
evaluation of HCV patients with cirrhosis [3]. Therefore, we
reasoned that sH2a might be regulated in a similar fashion as the
membrane ASGPR and could constitute a unique non-invasive
marker for hepatocyte function and fibrosis. Such a marker is
presently lacking, and despite proposed experimental markers or
combinations of routine tests, the gold standard continues to be
biopsy [11,12]. Besides its invasiveness and concomitant risks,
biopsy is not highly accurate in predicting fibrosis stage, because of
the sampling error due to the small volume of the samples and inter-
observer variation of up to 20% [13].
Experimental serum markers that have beenproposed for fibrosis
include extracellular matrix (ECM) macromolecules and their
degradation products. Unfortunately, these markers are not very
sensitiveandarenot liverspecific,theycanalsoreflectinflammatory
processes in other tissues. The same is true for the levels of normally
intracellular enzymes (alanine aminotransferase (ALT), aspartate
aminotransferase (AST), c-glutamyl transpeptidase (GGT), etc.).
These markers are indicative of liver damage but do not reflect
directly hepatocyte function. Function is diagnosed with classical
markers like albumin and prothrombin time (PT), but these are
sensitive only to severe disease. Likewise, methods that combine
several markers, like Fibrotest [14], are suitable to detect cirrhosis
and advanced fibrosis, but are not satisfactory for moderate fibrosis.
Therefore, it would be highly beneficial to have a non-invasive
serum marker that is a specific and sensitive test for hepatocyte
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we show for a cohort of HCV patients compared to healthy individuals
that ASGPR sH2a may be a valid candidate for such a role.
Materials and Methods
Ethics Statement
The study had a priori approval by Tel Aviv Sourasky Medical
Center hospital ethical committee according to the Helsinki
Declaration and written informed consent was obtained from all
participants.
Materials, antibodies and ELISA
Alkaline phosphatase (ALP) substrate p-nitrophenylphosphate (p-
NPP) was from Chemicon International (Temecula, CA). Imperial
protein stain was from (Pierce). Common reagents were from Sigma.
The preparation of a monoclonal antibody against sH2a and
the development of a competitive ELISA using this antibody were
described before [3]. ALP-conjugated goat anti-mouse IgG
antibody was from Jackson Laboratories (West Grove, PA).
Study subjects
Retrospective samples were from a group of healthy blood
donors and a cohort of consecutive pretreatment HCV-infected
patients at the Liver Unit, Tel Aviv Sourasky Medical Center.
Patients co-infected with HIV, HBV or with additional diseases
from other etiologies were excluded. Overweight healthy individ-
uals were also excluded.
Routine laboratory tests
Patients had routine laboratory tests performed by a certified
central lab, using common commercial methods. These tests
included total bilirubin, ALP, ALT, AST, GGT, albumin, serum
cholesterol, PT and HCV RNA level (RT-PCR). Similar tests were
done on healthy individuals except for PT and HCV RNA.
Liver histology
Percutaneous liver biopsy was performed using a Tru-Core II
[R] biopsy instrument under ultrasound guidance. A single
pathologist blinded to all clinical and serological results evaluated
all slides. Two patients where biopsies were found inadequate were
excluded from the study. Biopsies were METAVIR-scored [15] for
fibrosis stage and inflammation grade.
Statistical analysis
Comparison between groups of patients with regard to demo-
graphic (age, gender) and clinical parameters was performed using
Chi-square tests and Kruskal-Wallis non-parametric analysis of
variance (ANOVA), as applicable. The association between stage and
other parameters was examined using logistic regression. Results are
presented as odds ratio (OR), sensitivity and specificity with 95%
confidence intervals (CI). The diagnostic value of the combination
score ofsH2a and ALT with regard to fibrosis stages was evaluated by
the area under the receiver operating characteristic curve (AUROC).
The statistical significance level was set to 0.05. SPSS for Windows
software, version 14.0 (Chicago, IL) was used for the analysis.
Results
Comparison of the serum levels of sH2a in a cohort of
HCV patients with those in healthy individuals
We recently showed that sH2a is present at constant levels in
healthy individuals and strongly reduced in cirrhotic HCV patients
[3]. To investigate whether sH2a levels correlate with fibrosis, we
analyzed blindly and randomly, using an ELISA test that we had
developed, samples of serum obtained from 44 pretreatment HCV
patients and from 28 healthy individuals. Both populations had
male and female individuals with a similar wide range of ages
(Tables 1 and 2). HCV patients were all ambulatory and
minimally symptomatic. HCV patients had biopsies taken that
gave a median METAVIR- fibrosis stage of 1 and ranges 0–4. The
samples were also analyzed for a series of routine liver tests, and
the HCV patients showed significantly higher median levels than
the healthy individuals for bilirubin, ALP, ALT, AST, GGT but
only the median levels of ALT and AST were above the normal,
other median levels including those of albumin and PT were in the
normal range for both populations. The levels of sH2a were quite
constant for the healthy group, 150621 ng/ml, giving a median of
148 ng/ml, with a range of 105–188 ng/ml (interquartile range
(IQR): 136–163 ng/ml) (Table 2). For the HCV patients the sH2a
median was similar, 145 ng/ml, but the range was much wider,
31–237 ng/ml (Table 1).
We analyzed the relation between levels of the different markers
and fibrosis stage (Table 3). There was a moderate increase in the
likelihood for very high levels of ALT with increasing fibrosis
stage. There was a significant increase in the likelihood for high
levels of ALP although the percent of patients at fibrosis stages 3–4
with high ALP was still low (23%). There was a stronger
correlation between the levels of AST and GGT with fibrosis
stage, but few patients showed abnormal GGT and therefore its
correlation was not statistically significant. There was also a strong
correlation of likelihood for abnormal sH2a levels with increasing
fibrosis stage. This abnormal sH2a range was taken arbitrarily as
Table 1. HCV patients.
Characteristic Median [IQR] range
Male gender (%) 63.64
Age 41.5 29–53 19–64
Weight (kg) 73 66–84 56–127
total bilirubin (mg/dl) 2 1–3 0.3–4
bilirubin/normal
1 0.29 0.14–0.43 0.04–0.71
ALP (U/l) 75 62–96.5 44–194
ALP/normal
1 0.63 0.50–0.77 0.36–1.50
ALT (U/l) 75 43–103 30–458
ALT/normal
1 1.77 1.21–2.66 0.70–13.47
AST(U/l) 47 33–59 21–291
AST/normal
1 1.31 0.96–1.67 0.58–8.56
GGT (U/l) 33 23–52 10–246
GGT/normal
1 0.56 0.37–0.94 0.18–5.02
albumin (g/l) 45 43–47 38–54
albumin/normal
1 0.92 0.88–0.96 0.78–1.10
serum cholesterol (mg/dl) 166 142–199 102–323
cholesterol/normal
1 0.83 0.71–1.00 0.51–1.62
PT (sec) 12 11.4–12.2 10.4–14.8
PT/normal
1 0.81 0.77–0.82 0.70–0.99
sH2a (ng/ml) 145 118–167 31–237
Fibrosis stage 1 0–3 0–4
Inflammation grade 2 1–3 0–4
1Median of absolute values divided by upper limit of normal range.
doi:10.1371/journal.pone.0027210.t001
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and above the IQR of the healthy group. Most individuals with
abnormal sH2a had a decreased level of the marker in serum, but
a few (7) presented an abnormally high level. These few cases
might reflect the start of a neoplastic process as discussed later.
There was considerable difference in the percent of individuals
with abnormal sH2a between the group with mild or moderate
fibrosis (stages 0–2) (35.5%) to those with advanced fibrosis (stages
3–4) (69.2%) (Table 3). As shown in Fig. 1A, there was a steady
increase in the number of individuals with an abnormal level of
sH2a with increasing fibrosis stage. All patients at stage 4 showed
abnormal sH2a levels, but because of the small number of samples
at this stage they were joined with those at stage 3 to achieve
statistical significance (Fig. 1A). Most noteworthy, sH2a shows a
change to abnormal levels in a significant portion of patients at
mild and intermediate fibrosis stages (1–2).
A combined score of the levels of sH2a and ALT
Given that sH2a levels would reflect liver function, whereas the
levels of ALT are indicative of liver damage, we reasoned that a
combination of these values would compensate for individual
fluctuations in the overall state of each patient. An algorithm
combining the levels of sH2a with those of ALT, gave a score of
zero for the healthy individuals and a very good correlation with
fibrosis stage for the HCV patients (Fig. 1B). Details of the
calculation of the combined value are given in the legend to
Fig. 1B. Using this combined score of sH2a and ALT levels, the
AUROC calculated for advanced fibrosis (stages 3–4) was very
high, 0.863 (Fig. 2B), compared to that of sH2a alone (0.724,
Fig. 2A). The AUROC was also high for this combined value,
0.786, when calculated for intermediate fibrosis (stages 2–3)
(Fig. 2C). For intermediate and significant fibrosis (stages 2–4), at a
sensitivity of 65%, the specificity of sH2a and ALT was similar,
71% and 73% respectively, but the accuracy of sH2a was higher,
68% versus 58% for ALT. At the same sensitivity the combination
score gave a high specificity, 85%.
Discussion
Our results reveal ASGPR sH2a as a novel non-invasive marker
for liver fibrosis and function. SH2a, the enzymes ALT, AST,
GGT and ECM components like collagen and hyaluronic acid
(HA) reflect different stages of the fibrogenic process. Hepatocytes
are targets for most insults to the liver, including hepatitis viruses
and alcohol [16]. The damage caused abrogates the function of
the hepatocytes and leads to subsequent release of inflammatory
factors that activate hepatic stellate cells and cause them to
differentiate to myofibroblasts that secrete ECM components and
matrix metalloproteinases that degrade them [17,18]. The
Table 2. Healthy individuals.
Characteristic Median [IQR] range
Male gender (%) 53.57
Age 40.00 29–48 22–64
total bilirubin (mg/dl) 0.36 0.22–0.50 0.06–1.05
bilirubin/normal 0.05 0.05–0.16 0.009–0.42
ALP (U/l) 48.00 36–55 22–88
ALP/normal 0.35 0.33–0.51 0.17–0.68
ALT (U/l) 19.00 14–27 9–38
ALT/normal 0.42 0.37–0.65 0.26–1.03
AST(U/l) 27.00 20–31 14–39
AST/normal 0.67 0.49–0.89 0.35–1.08
GGT (U/l) 12.50 3–18 1–38
GGT/normal 0.18 0.06–0.38 0.02–0.62
albumin (g/l) 43.00 41–46 31–50
albumin/normal 1.24 1.20–1.39 0.89–1.52
serum cholesterol (mg/dl) 190.00 167–219 101–274
cholesterol/normal 0.86 0.83–1.09 0.50–1.37
sH2a (ng/ml) 148 136–163 105–188
doi:10.1371/journal.pone.0027210.t002
Table 3. Univariate analysis of correlation of characteristics with advanced fibrosis.
Characteristic Healthy HCV patients P value Odds ratio (95% CI)
Fibrosis stage
N (n=28) 0–2 (n=31) 3–4 (n=13)
Male gender
1 15 (53.6) 18 (58.1) 10 (76.9) 0.235 2.41 (0.55–10.52)
Median age (IQR) 40 (29–48) 35 (27–49) 51 (47–55) 0.019 1.08 (1.01–1.16)
bilirubin/normal .1 0 (0) 0 (0) 0 (0) - -
ALP/normal .1 0 (0) 1 (3.23) 3 (23.1) 0.027 10.00 (0.92–108.33)
ALT/normal .2 0 (0) 10 (32.3) 8 (61.5) 0.047 4.20 (1.09–17.32)
AST/normal .1 1 (3.6) 18 (58.1) 12 (92.3) 0.008 9.33 (1.81–48.24)
GGT/normal .1 0 (0) 5 (16.1) 5 (38.5) 0.075 3.71 (0.83–16.55)
albumin/normal ,0.8 0 (0) 1 (3.23) 0 (0) 0.529 1.4 (1.16–1.70)
cholesterol/normal .1.2 2 (7.1) 1 (3.23) 1 (7.69) 0.476 2.73 (0.16–47.46)
abnormal sH2a 6 (21.4) 11 (35.5) 9 (69.2) 0.040 4.09 (1.02–16.40)
(sH2a ,125 ng/ml or .=175 ng/ml)
1Data is presented as n (%) except for age, which is presented as median (IQR); odds ratios are from simple logistic regression, using the forced entry method, on each
variable. The dependent variable in the regression is state and the outcome is METAVIR score (1 if state is 3–4); CI, confidence interval presented for each explanatory
variable.
doi:10.1371/journal.pone.0027210.t003
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accumulate, originating fibrosis that further impairs liver function
and develops to cirrhosis (Fig. 3). Thus, in the chain of events that
leads to fibrogenesis, HA is a late indicator of the production of
ECM; the enzymes are released by damaged cells; whereas we
suggest that sH2a is a marker of liver function, correlating to the
mass of functional hepatocytes (Fig. 3). Reduction of the levels of
sH2a would reflect early events in the fibrogenic process, affecting
hepatocyte function. We can speculate that the few cases where
sH2a levels were abnormally high might indicate the start of a
neoplastic process with proliferation of hepatocytes that express
high levels of the ASGPR. At later tumorigenic stages, with
dedifferentiation, one would expect again very low levels of sH2a.
This is a subject that requires further studies. On the other hand,
during the development of fibrosis, temporary changes in the total
hepatocyte function (indicated by sH2a levels) may not occur
simultaneously with changes in the release and clearance of
damage markers (e.g. ALT). The function (sH2a) and damage
markers give complementary information and when combined
provide an accurate prediction of the fibrosis stage, including early
and intermediate stages of fibrosis that other markers fail to detect.
In our combined algorithm, the higher weight given to sH2a
reduces the influence of ALT increases due to non-hepatic sources.
SH2a is liver-specific, but we still do not know whether its blood
levels are modulated or not in other diseases, for example in
kidney disease, which could be a potential limitation.
Figure 1. Box plots of sH2a and of the combination score of sH2a and ALT versus fibrosis stage. A) The levels of sH2a in sera were
compared between a group of 28 healthy individuals (N) and 44 HCV patients with different METAVIR fibrosis stages (0–4). Plotted is the percent of
individuals in each group that showed abnormal sH2a levels (,125 ng/ml or .=175 ng/ml). In parenthesis are the numbers of individuals in each
group. P value (Chi-square tests, comparing stages 3+4 to 0)=0.034. B) The serum levels of sH2a and ALT for each healthy individual and for each
HCV patient were joined in a combined score. Shown is a boxplot of the combination score of sH2a and ALT for healthy individuals (N) and for HCV
patients grouped by METAVIR fibrosis stage (0–4). The box height indicates the IQR in each group. The thick horizontal bar is the median. The
whiskers extend to the farthest non-outlier value smaller than 1.56IQR. Circles indicate ‘‘mild’’ outliers (,36IQR) and asterisks show ‘‘extreme’’
outliers (.36IQR). P,0.0001. The combination score of sH2a and ALT was calculated as follows: Combination score=(1 if normalized ALT,1.1, 2 if
normalized ALT 1.1–2, 3 otherwise)6(2 if sH2a 125–175 ng/ml, 4 if sH2a 113–124 ng/ml or 176–207 ng/ml, 6 otherwise)-2.
doi:10.1371/journal.pone.0027210.g001
Figure 2. ROC plots of sH2a and of the combination score of sH2a and ALT. A) Receiver operating characteristic (ROC) plot of sH2a values
for advanced fibrosis and cirrhosis (METAVIR 0–1 vs 3–4) for the group of 44 HCV patients. B–C) ROC plots of the combined scores of sH2a and ALT
were made for advanced fibrosis and cirrhosis (METAVIR 0–1 vs 3–4) (B) or for intermediate fibrosis (METAVIR 0–1 vs 2–3) (C) of the same group of
patients.
doi:10.1371/journal.pone.0027210.g002
sH2a, Non-Invasive Liver Fibrosis Marker
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mild from very severe disease ([14] and our unpublished results).
With our sH2a, ALT combination score a cutoff ,4 gives a
negative predictive value for fibrosis ,2 of 92.9% and a positive
predictive value for fibrosis .=2 of 62.1%. This fairs very well
even when comparing with the predictive value of other markers
for severe disease. For example, in one study a 60 mg/l HA cutoff
gave a high negative predictive value (99.5%), for the absence of
cirrhosis but very low positive predictive value in predicting
cirrhosis (30%) [19]. This was improved by combination of the
levels of HA with those of AST and albumin, which gave a good
prediction for absence of severe fibrosis but unsatisfactory for
intermediate levels [20]. Similarly, a better known combination
method, Fibrotest, is useful for detecting advanced fibrosis but not
very satisfactory at intermediate levels [14]. It has been argued
that biopsy itself has only an 80% accuracy [21]. The simple
combination of sH2a and ALT gave an AUROC of 0.786 for
intermediate fibrosis (stages 2–3), which is better than other
markers or combinations of markers. For advanced fibrosis and
cirrhosis (stages 3–4) the AUROC obtained was 0.863, which
compares very favorably with the AUROC obtained for severe
disease with combinations of other markers, e.g. AUROC=0.76
for significant fibrosis and AUROC=0.82 for cirrhosis in an AST
to platelet ratio [22], AUROC=0.81 for cirrhosis with combined
HA, TIMP-1, and platelet count [23] and AUROC=0.84 with
Fibrotest [21].
A method that is being increasingly used is transient
elastography (FibroScan), which measures liver stiffness, which in
turn is correlated to fibrosis stage. Using this method the AUROC
values obtained for significant fibrosis ranged from 0.76 to 0.83,
quite suitable but lower than with the combination of sH2a with
ALT [24,25]. Like in other methods, the values that transient
elastography provides for moderate fibrosis are not satisfactory; for
example in one recent study it could not statistically differentiate
stage 2 from 0–1 [26]. In addition, transient elastography values
are inaccurate in obese patients or in those with fatty liver and the
method cannot be used in patients with ascites.
The sensitive assessment of hepatocyte function by sH2a could
allow the measuring of success of patient treatment. In a
longitudinal study during treatment of HCV patients, the change
in sH2a levels correlated, unlike other markers, with the success of
the therapy (our unpublished results). Studies of membrane
ASGPR levels upon resection and recovery or in liver transplan-
tation suggest that sH2a could also be measured to monitor these
interventions [27].
SH2a should be further evaluated as it emerges as a good
candidate for a suitable liver fibrosis marker. It has been argued
that such a marker should: be specific for the liver, be readily
available, not be subject to false positive results, identify the stage
of fibrosis [13].
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